Advertisement
IMVT vs LXEO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Buy and LXEO is a Hold.
IMVT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for IMVT turned positive on October 22, 2026. Looking at past instances where IMVT's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMVT's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on IMVT as a result. In 70 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
Following a +5.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in 203 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
IMVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 57 cases where IMVT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for IMVT entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.398) is normal, around the industry mean (2.904). P/E Ratio (-10.641) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 58 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for LXEO turns positive, indicating new upward trend
LXEO saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator turned positive. In 42 of the 48 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LXEO's RSI Oscillator exited the oversold zone, 12 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for LXEO just turned positive on October 20, 2026. Looking at past instances where LXEO's MACD turned positive, the stock continued to rise in 26 of 31 cases over the following month. The odds of a continued upward trend are 84%.
Following a +5.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where LXEO advanced for three days, in 152 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
LXEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 37 cases where LXEO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for LXEO entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.128) is normal, around the industry mean (2.904). P/E Ratio (-3.670) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. LXEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IMVT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | |
PROFIT vs RISK RATING 1..100 | 58 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 61 | |
P/E GROWTH RATING 1..100 | 20 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| IMVT | LXEO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 87% | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 88% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 84% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 89% |
| Advances ODDS (%) | 1 day ago 76% | 1 day ago 84% |
| Declines ODDS (%) | 4 days ago 81% | 11 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 72% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMVT’s FA Score shows that 1 FA rating(s) are green while LXEO’s FA Score has 1 green FA rating(s).
- IMVT’s FA Score: 1 green, 4 red.
- LXEO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMVT’s TA Score shows that 5 TA indicator(s) are bullish while LXEO’s TA Score has 5 bullish TA indicator(s).
- IMVT’s TA Score: 5 bullish, 3 bearish.
- LXEO’s TA Score: 5 bullish, 3 bearish.
Price Growth
IMVT (@Biotechnology) experienced а +1.63% price change this week, while LXEO (@Biotechnology) price change was +3.19% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -11.00%, and the average quarterly price growth was -16.20%.
Reported Earning Dates
IMVT is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMVT and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.
| Ticker / NAME | Correlation To IMVT | 1D Price Change % | ||
|---|---|---|---|---|
| IMVT | 100% | +2.96% | ||
| ROIV - IMVT | 64% Loosely correlated | +6.08% | ||
| LXEO - IMVT | 49% Loosely correlated | +3.86% | ||
| KURA - IMVT | 47% Loosely correlated | -22.98% | ||
| PTGX - IMVT | 46% Loosely correlated | +2.23% | ||
| SYRE - IMVT | 46% Loosely correlated | -0.23% | ||
More | ||||
LXEO and
Correlation & Price change
A.I.dvisor indicates that over the last year, LXEO has been loosely correlated with PRME. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if LXEO jumps, then PRME could also see price increases.
| Ticker / NAME | Correlation To LXEO | 1D Price Change % | ||
|---|---|---|---|---|
| LXEO | 100% | +3.86% | ||
| PRME - LXEO | 53% Loosely correlated | +9.23% | ||
| SLDB - LXEO | 52% Loosely correlated | +3.82% | ||
| KURA - LXEO | 51% Loosely correlated | -22.98% | ||
| EDIT - LXEO | 51% Loosely correlated | +4.62% | ||
| RCKT - LXEO | 50% Loosely correlated | +3.98% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PRCS | 29.82 | 0.95 | +3.30% |
| Parnassus Core Select ETF | |||
| TAOZ | 91.33 | 1.78 | +1.98% |
| Thornburg American Opportunities Fund (TAOZ) | |||
| FNDE | 40.83 | 0.55 | +1.37% |
| Schwab Fundamental Emerging Markets Equity ETF (FNDE) | |||
| IWMW | 37.39 | 0.42 | +1.15% |
| iShares IWM Premium Income+ ETF (IWMW) | |||
| DMBS | 47.22 | 0.18 | +0.38% |
| DoubleLine Mortgage ETF (DMBS) | |||